Showing 3551-3560 of 5257 results for "".
- ACR Update: TAK-279 Shows Promise in Phase 2b Psoriatic Arthritis Studyhttps://practicaldermatology.com/news/acr-update-tak-279-shows-promise-in-phase-2b-psoriatic-arthritis-study/2462119/Takeda's investigational tyrosine kinase 2 (TYK2) inhibitor TAK-279 showed significant efficacy in patients with active psoriatic arthritis, according to Phase 2b data slated to be presented at the American College of Rheumatology's (ACR) annual meeting in San Diego, California.
- National Rosacea Society Awards 2023 Research Grantshttps://practicaldermatology.com/news/national-rosacea-society-awards-2023-research-grants/2462117/The National Rosacea Society (NRS) has announced that it will contribute funding for one new study, continue funding for two ongoing studies, as part of its grant program to advance rosacea research. "Ongoing research into the pathologic processes of rosacea has ena
- Positive Clinical Data Show Potential of STP705 for Focal Fat Reductionhttps://practicaldermatology.com/news/sirnaomics-presents-positive-clinical-data-of-stp705-for-focal-fat-reduction/2462111/New data for the investigative STP705 injectible for focal fat reduction (FFR) are "encouraging," according to the manufacturer, who presented at the 2023 Fall Clinical Dermatology Conference, which took place October 22–25 in Las Vegas. The safety an
- Study Highlights Potential Minoxidil Shortagehttps://practicaldermatology.com/news/study-highlights-potential-minoxidil-shortage/2462107/Minoxidil may be in short supply at some pharmacies, potentially jeopardizing patients’ efforts to treat hair loss, according to new research in the
- Tralokinumab Shows Improvements in Dupilumab Patients Up to 52 Weekshttps://practicaldermatology.com/news/tralokinumab-shows-improvements-in-dupilumab-patients-up-to-52-weeks/2462103/The results of a phase 3 trial expands on the efficacy and safety profile of tralokinumab, the first monoclonal antibody (mAb) that targets IL4Rα, blocking signaling of interleukin (IL)-13 and IL-4. Approved in the EU
- New Insights on the Genetic Link Between Skin Tone and Ancestral Originhttps://practicaldermatology.com/news/new-insights-on-the-genetic-link-between-skin-tone-and-ancestral-origin/2462096/The link between skin pigmentation and ethnicity is more complicated than previously believed, according to new research published in the journal eLife. The team has confirmed that genes associated with East Asian and Native American anc
- Nemolizumab Continues to Wow in PNhttps://practicaldermatology.com/news/nemolizumab-shows-continued-promise-in-pn/2462095/Nemolizumab monotherapy significantly and rapidly improves itch and skin lesions in patients with prurigo nodularis, with clinically meaningful improvements seen as early as week four, according to results from the OLYMPIA 2 Trial, which appears in the
- Almirall Seeks Proposals to Better Understand Key Pathological Mechanisms of Skin Diseaseshttps://practicaldermatology.com/news/almirall-seeks-proposals-to-better-understand-key-pathological-mechanisms-of-skin-diseases/2462090/Almirall S.A. is calling for proposals to better understand key pathological mechanisms of several skin diseases through AlmirallShare, its open innovation platform. Almirall’s objective through this call is to identify and explore, through collaboration w
- Man Vs. Machine: AI May Be as Reliable as Doctors for Diagnosing Skin Cancerhttps://practicaldermatology.com/news/man-vs-machine-ai-may-be-as-reliable-as-doctors-for-diagnosing-skin-cancer/2462088/Skin cancer diagnoses using artificial intelligence (AI) are as reliable as those made by medical experts, but doctors are clearly superior when it came to treatment decisions. These are the main takeaways from research looking at AI applications under realisti
- Breaking News From Fall Clinical: Lebrikizumab Performs Well for Up to Two Years in ADhttps://practicaldermatology.com/news/ears-experienced-sustained-skin-clearance-itch-relief-and-reduced-disease-severity-with-monthly-maintenance-dosing-as-demonstrated-in-the-adjo/2462083/Patients with moderate-to-severe atopic dermatitis who continued treatment with investigational lebrikizumab for up to two years experienced sustained skin clearance, itch relief and reduced disease severity with monthly maintenance dosing, according to data from the ADjoin long-term extensi